iwCLL 2019 | MRD assessment in the era of novel therapies for CLL
Carol Moreno
• 21 Sep 2019
Carol Moreno, MD, PhD, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, emphasises that further investigation must be done as to the prognostic utility of measurable residual disease (MRD). This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.
